EUVIMEDEUVIMED entdecken
Multizentrische Studie

Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort

Ting-Chun Huang, Po-Hsueh Su, Hui-Wen Lin, Po-Tseng Lee, Yu Liao, Chao-Yu Chen, Li-Hao Yap, Sheng-Hsiang Lin, Yi-Heng Li

Heart Rhythm · 2026-08 · 23 (8) · e1372-e1382

DOI: 10.1016/j.hrthm.2026.02.042 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Heart Rhythm, 2026-08. Verfasst von Ting-Chun Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Cardiology, Department of Internal M…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anti-Arrhythmia Agents, Percutaneous Coronary Intervention, Coronary Artery Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Cheng Kung University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Class Ic antiarrhythmic drugs (AADs) are generally avoided in patients with coronary artery disease owing to concerns about their proarrhythmic potential. However, their impact on mortality and arrhythmic risk in patients with chronic coronary syndrome (CCS) who have undergone percutaneous coronary intervention (PCI) remains unclear. OBJECTIVE: This study aimed to assess the safety of class Ic AADs compared with nonuse in patients with new-onset atrial fibrillation (NOAF) after PCI. METHODS: A retrospective cohort study using Taiwan's National Health Insurance Research Database included adults with NOAF after PCI. Participants were divided into class Ic users and nonusers. Outcomes evaluated included major adverse cardiovascular events (MACEs), all-cause mortality, ventricular arrhythmia, and cerebrovascular events. Cox models and competing risk analyses estimated hazard ratios. RESULTS: Among 3750 patients (mean age 74.70; 69.33% male; CHA2DS2-VASc score 3.98), class Ic users showed significantly lower risks of MACEs (adjusted subdistribution hazard ratio [asHR] 0.64; 95% confidence interval [CI] 0.59-0.68; P < .01), all-cause mortality (asHR 0.61; 95% CI 0.57-0.66; P < .01), and cerebrovascular events (asHR 0.81; 95% CI 0.66-0.99; P = .04). No increased risk of ventricular arrhythmia was observed (asHR 0.89; 95% CI 0.69-1.15; P = .37). CONCLUSION: In patients with CCS who developed NOAF, the use of class Ic AADs was associated with significantly lower risks of MACEs, all-cause mortality, and cerebrovascular events and without an increased risk of ventricular arrhythmia. These findings suggest that class Ic agents may be a safe and effective option for rhythm control in carefully selected patients with CCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnti-Arrhythmia AgentsPercutaneous Coronary InterventionCoronary Artery DiseaseHumansMaleFemaleRetrospective StudiesAgedTaiwanFollow-Up StudiesTreatment OutcomeRisk AssessmentRisk FactorsIncidenceSurvival Rate

Stichwörter der Autor:innen

AntiarrhythmicsAtrial fibrillationCoronary artery diseasePercutaneous coronary interventionsVentricular arrhythmia

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine,…
  • Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Cardiology, Department of Internal Medic…
  • Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung Uni…
  • Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: heng@mail.ncku.edu.tw.

Förderung

  • National Cheng Kung University Hospital

Zitieren

APA

Huang, T. C., Su, P. H., Lin, H. W., Lee, P. T., Liao, Y., Chen, C. Y., Yap, L. H., Lin, S. H., & Li, Y. H. (2026). Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort. Heart Rhythm, 23(8), e1372-e1382. https://doi.org/10.1016/j.hrthm.2026.02.042

Vancouver

Huang TC, Su PH, Lin HW, Lee PT, Liao Y, Chen CY, et al. Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort. Heart Rhythm. 2026;23(8):e1372-e1382. doi:10.1016/j.hrthm.2026.02.042

BibTeX
@article{Huang2026,
  author = {Huang, Ting-Chun and Su, Po-Hsueh and Lin, Hui-Wen and Lee, Po-Tseng and Liao, Yu and Chen, Chao-Yu and Yap, Li-Hao and Lin, Sheng-Hsiang and Li, Yi-Heng},
  title = {Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort},
  journal = {Heart Rhythm},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {e1372--e1382},
  doi = {10.1016/j.hrthm.2026.02.042}
}
Kostenlos starten →